CUAMC
CTMX icon

China Universal Asset Management Company’s CytomX Therapeutics CTMX Stock Holding History

China Universal Asset Management Company’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$259K Buy
55,068
+27,459
+99% +$139K 0.02% 330
2025
Q4 		$118K Buy
+27,609
New +$105K 0.01% 400
2022
Q4 		– Sell
-617
Closed -$1K – 414
2022
Q3 		$1K Buy
+617
New +$950 ﹤0.01% 391

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

China Universal Asset Management Company's CTMX Position: Q1 2026 in Review

China Universal Asset Management Company increased its CytomX Therapeutics (CTMX) stake by 99% in Q1 2026, buying an estimated $139K and bringing the position to 55,068 shares worth $259K. The position accounts for 0.02% of the portfolio, ranked #330.

China Universal Asset Management Company first reported a position in CTMX in Q3 2022 and has held it in 3 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • China Universal Asset Management Company held 55,068 shares of CytomX Therapeutics worth $259K as of Q1 2026.
  • China Universal Asset Management Company bought 27,459 CytomX Therapeutics shares in Q1 2026, an estimated $139K.
  • CytomX Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q1 2026, its #330 holding.
  • China Universal Asset Management Company first reported a position in CytomX Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.